WhatA lightweight local daemon that manages CPU, memory, disk I/O, and battery impact of AI coding agents, preventing them from monopolizing developer workstations during long autonomous runs.
SignalDevelopers report that aggressive agents like Fable rebuild entire apps, run full test suites, and watch every log — destroying their machine's performance and battery to the point where they can't do other work, making an objectively better model not worth using.
Why NowAI agents have shifted from short request-response interactions to hour-long autonomous plan-and-implement cycles that treat local machines as build servers, a usage pattern that existing OS-level resource management was never designed to handle.
MarketMillions of developers using local AI coding agents; natural fit as a developer tool sold per-seat ($10-20/mo). No direct competitor addresses this specific problem — existing tools like cgroups are too low-level for most developers.
MoatAgent-specific resource profiling data across different models and tasks enables intelligent throttling that balances agent effectiveness against machine usability — a tuning challenge that requires significant real-world usage data to solve well.
CRISPR Delivery Platform for Solid Tumor TherapeuticsP7/10A biotech company focused specifically on solving the delivery problem for CRISPR-based cancer therapies, developing novel lipid nanoparticle or viral vector systems that can efficiently transport CRISPR payloads to solid tumors in vivo.
CRISPR Cancer Diagnostics for Undruggable MutationsP6/10A diagnostic platform that profiles patients' tumors for the specific genomic amplifications and mutations that CRISPR-shredding approaches can target, enabling oncologists to match patients to emerging CRISPR therapies.
Biotech Translation Tracker for Informed InvestorsC5/10A platform that tracks the real progress of preclinical and clinical-stage biotech breakthroughs — from lab results through delivery challenges, trial phases, and regulatory milestones — giving investors and patients an honest, hype-free assessment of how close therapies actually are to market.
Viral Vector Therapy Development Platform as ServiceC6/10A contract development platform that helps biotech startups and academic labs design, optimize, and manufacture viral vector (AAV/lentivirus) delivery systems for gene therapies, positioning as the picks-and-shovels play in gene therapy.
Automated Cost Guardrails for AI Agent OperationsP7/10A middleware layer that sits between AI agents and cloud/API services, enforcing hard spending limits, rate controls, and anomaly detection before any resource is consumed.
Prepaid Spending Caps for Cloud and API ServicesC6/10A financial wrapper service that lets developers provision hard-capped, prepaid budgets for cloud and API usage — once the balance hits zero, all calls stop instantly.